IN2014DN00123A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00123A
IN2014DN00123A IN123DEN2014A IN2014DN00123A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A IN 123DEN2014 A IN123DEN2014 A IN 123DEN2014A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A
Authority
IN
India
Prior art keywords
compounds
mek
inflammation
inhibitors
cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Ramulu Poddutoori
Can Wang
Xianglin Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to IN123DEN2014 priority Critical patent/IN2014DN00123A/en
Publication of IN2014DN00123A publication Critical patent/IN2014DN00123A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN123DEN2014 2011-06-09 2012-06-06 IN2014DN00123A (en, 2012)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN123DEN2014 IN2014DN00123A (en, 2012) 2011-06-09 2012-06-06

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1634DE2011 2011-06-09
CN201210175145 2012-05-31
IN123DEN2014 IN2014DN00123A (en, 2012) 2011-06-09 2012-06-06
PCT/IB2012/052860 WO2012168884A1 (en) 2011-06-09 2012-06-06 Heterocyclic sulfonamide derivatives

Publications (1)

Publication Number Publication Date
IN2014DN00123A true IN2014DN00123A (en, 2012) 2015-05-22

Family

ID=46384435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN123DEN2014 IN2014DN00123A (en, 2012) 2011-06-09 2012-06-06

Country Status (10)

Country Link
EP (1) EP2718276A1 (en, 2012)
JP (1) JP2014517004A (en, 2012)
KR (1) KR20140034898A (en, 2012)
AU (1) AU2012265844A1 (en, 2012)
BR (1) BR112013031201A2 (en, 2012)
CA (1) CA2838029A1 (en, 2012)
EA (1) EA201391820A1 (en, 2012)
IN (1) IN2014DN00123A (en, 2012)
MX (1) MX2013014398A (en, 2012)
WO (1) WO2012168884A1 (en, 2012)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013094546A1 (ja) * 2011-12-19 2013-06-27 住友化学株式会社 スルホン酸塩の製造方法
EP2742940B1 (en) 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
CN104886052B (zh) * 2015-06-02 2016-08-31 吉林省八达农药有限公司 一种环丙磺酰胺的应用
US10736897B2 (en) * 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2019183385A1 (en) * 2018-03-22 2019-09-26 University Of Rochester Mapk/erk inhibition for ovarian and other cancers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (en, 2012) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3398382B2 (ja) 1992-10-28 2003-04-21 ジェネンテク，インコーポレイテッド 血管内皮細胞増殖因子アンタゴニスト
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE205483T1 (de) 1995-03-30 2001-09-15 Pfizer Chinazolinderivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
NZ312665A (en) 1995-07-06 1999-08-30 Novartis Ag Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
WO1998010121A1 (en) 1996-09-06 1998-03-12 Obducat Ab Method for anisotropic etching of structures in conducting materials
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE69927790T2 (de) 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
AU766081B2 (en) 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2006083137A (ja) * 2004-09-17 2006-03-30 Sankyo Co Ltd 免疫抑制剤
US8648116B2 (en) * 2005-07-21 2014-02-11 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
CN101663279A (zh) * 2007-01-19 2010-03-03 阿迪生物科学公司 Mek抑制剂
EP2276747A1 (en) * 2008-03-11 2011-01-26 Cellzome Limited Sulfonamides as zap-70 inhibitors
AU2009266956B2 (en) * 2008-07-01 2014-03-20 Genentech, Inc. Bicyclic heterocycles as MEK kinase inhibitors
CA2761108A1 (en) * 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
CN102134218A (zh) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
CN102596951B (zh) * 2009-11-04 2015-04-15 诺华股份有限公司 用作mek抑制剂的杂环磺酰胺衍生物
KR20120102750A (ko) * 2009-12-08 2012-09-18 노파르티스 아게 헤테로시클릭 술폰아미드 유도체

Also Published As

Publication number Publication date
MX2013014398A (es) 2014-03-21
EP2718276A1 (en) 2014-04-16
WO2012168884A1 (en) 2012-12-13
KR20140034898A (ko) 2014-03-20
JP2014517004A (ja) 2014-07-17
CA2838029A1 (en) 2012-12-13
AU2012265844A1 (en) 2013-05-02
EA201391820A1 (ru) 2014-12-30
BR112013031201A2 (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2012214029A8 (en) Rorgammat inhibitors
ZA201700572B (en) Therapeutically active compounds and their methods of use
IN2014KN00769A (en, 2012)
IN2015DN01156A (en, 2012)
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
EP2750694B8 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
IN2014MN00948A (en, 2012)
MX349159B (es) Derivados deuterados de ivacaftor.
IN2014MN00987A (en, 2012)
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
IN2015DN01119A (en, 2012)
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
MX348726B (es) Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.
MX345127B (es) Derivados de tiazol.
HK1223924A1 (zh) 治疗活性化合物及其使用方法
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
IN2014DN00123A (en, 2012)
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
IN2014DN03010A (en, 2012)
IN2014CN02315A (en, 2012)
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
AU2012307449A8 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles